StrideBio, an emerging startup focusing on gene therapies which closed on a big $81.5 million round of venture capital in March, is partnering with Duke University as it expands efforts to create next-generation therapies.
StrideBio is a North Carolina-based biotechnology firm that develops and commercializes gene therapies for the treatment of CNS and cardiovascular disorders.